



<b>Name</b>	Yunsuk Choi	
<b>Current Position</b>	Associate professor	
<b>Country</b>	Republic of Korea	
<b>Major Field</b>	Hematology	

## Educational Background

The Graduate School of the University of Ulsan College of Medicine, Seoul, South Korea	2010-2012
<b>Doctor of Medicine</b>	
The Graduate School of the University of Ulsan, Seoul, South Korea	2008-2010
<b>Master of Medicine</b>	
Hanyang University College of Medicine, Seoul, South Korea	1999-2005
<b>Bachelor of Medicine</b>	

## Professional Experience

Asan Medical Center, South Korea	2022-present
<b>Department of Hematology, Associate professor</b>	
Ulsan University Hospital, Ulsan, South Korea	2021-2022
<b>Department of Hematology and Oncology, Associate professor</b>	
Ulsan University Hospital, Ulsan, South Korea	2016-2020
<b>Department of Hematology and Oncology, Assistant professor</b>	
Ulsan University Hospital, Ulsan, South Korea	2015- 2016
<b>Department of Hematology and Oncology, Clinical assistant professor</b>	
Asan Medical Center, Seoul, South Korea	2014-2015
<b>Department of Hematology, clinical instructor</b>	
Konkuk Universtiy Hospital, Seoul, South Korea	2013.2-2014
<b>Department of Hemato-oncology, Clinical assistant professor</b>	
Asan Medical Center, Seoul, South Korea	2012-2013
<b>Heath Promotion and Screening Center, Staff</b>	

## Other Experience and Professional Memberships

<b>Korean Medical Association</b>	
Member	2005-Present
<b>Korean Association of Internal Medicine</b>	
Member	2006-Present
<b>Korean Society of Hematology</b>	
Member	2009-Present
<b>Korean Association for Clinical Oncology</b>	
Member	2010-Present

**American Society of Clinical Oncology**

Member

2010-Present

**American Society of Hematology**

Member

2018-Present

**Main Scientific Publications**

The soluble VCAM-1 level is a potential biomarker predicting severe acute graft versus host disease after allogeneic hematopoietic cell transplantation. Sook-Kyoung Heo, Eui-Kyu Noh , Yoo Jin Lee, Yerang Shin , Youjin Kim, Hyeon-Su Im , Hyeyeong Kim , Su Jin Koh , Young Joo Min , Jae-Cheol Jo and **Yunsuk Choi**, BMC Cancer (2022) 22(1):997

Second allogeneic hematopoietic stem cell transplantation in patients with acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation, **Choi Y**, Choi EJ, Lee JH, Lee KH, Jo JC, Park HS, Lee YJ, Seol M, Lee YS, Kang YA, Jeon M, Lee JH. Clin Transplant. 2021 Mar;35(3):e14199

Association of serum hemoglobin level with the risk of carotid plaque beyond metabolic abnormalities among asymptomatic adults without major adverse clinical events: a cross-sectional cohort study.

**Choi Y**, Won KB, Kang HH, Chang HJ.. BMC Cardiovasc Disord. 2021 Mar 2;21(1):35.

Late complications and quality of life assessment for survivors receiving allogeneic hematopoietic stem cell transplantation. Cheon J, Lee YJ, Jo JC, Kweon K, Koh S, Min YJ, Park SH, Lee SH, Kim HJ, **Choi Y**. Supportive Care Cancer 2021 Feb 29; 2.

Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study. **Choi Y**, Lee JH, Jung CW, Jo JC, Kim JS, Kim I, Park S, Cheong JW, Park SH, Kim SY, Lee HG. Korean J Intern Med. 2021 Jan 36;1

Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death. Heo SK, Noh EK, Yu HM, Kim DK, Seo HJ, Lee YJ, Cheon J, Koh SJ, Min YJ, **Choi Y**, Jo JC. Heo SK, et al. BMC Cancer. 2020 Dec 4;20(1):1193. doi: 10.1186/s12885-020-07701-8.

Monosomal karyotype affecting outcomes of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission. **Choi Y**, Lee JH, Lee JH, Park HS, Choi EJ, Jo JC, Lee YJ, Lee YS, Kang YA, Lee KH. Eur J Haematol. 2020 Sep;105:262-273.

CD45dimCD34+CD38-CD133+ cells have the potential as leukemic stem cells in acute myeloid leukemia. Heo SK, Noh EK, Ju LJ, Sung JY, Jeong YK, Cheon J, Koh SJ, Min YJ, **Choi Y**, Jo JC. BMC Cancer. 2020 Apr 6;20(1):285.